Background: We evaluated reliability and clinical usefulness of genotypic resistance testing (GRT), in patients failing combination antiretroviral therapy (cART) with viremia levels 50-1000 copies/mL, for whom GRT is generally not recommended by current guidelines. Methodology: Genotyping success rate (GSR) was evaluated in 12828 HIV-1 plasma samples with viremia >50 copies/mL, tested using the commercial ViroSeq HIV-1 Genotyping System or a homemade system. Samples were stratified in 6 groups according to different viremia levels (50-200; 201-500; 501-1000; 1001-10000; 10001-100000; >100000 copies/mL). Phylogenetic analysis was performed to test the reliability and reproducibility of the GRT at low viremia levels. Drug-resistance was evaluated in 3895 samples from 2200 treatment failing patients (viremia >50 copies/mL). Multivariable logistic regression analysis was used to evaluate the impact of viremia-levels at genotyping on the prevalence of drug-resistance. Resistance mutations panelled in the IAS list 2013 have been considered. Results: Samples analysed were mainly from patients carrying a subtype B virus (80%), but also from patients carrying non-B subtype viruses (20%, prevalence of the most prevalent ones: CRF02_AG=4.7%; C=4.3%; F=3.3%). Overall, GSR was 96.4% and was independent from subtype. Viremia levels of 50-200 and 201-500 copies/mL afforded GSR of 67.2% and 88.1%, respectively, reaching 93.2% at 501-1000 copies/mL and ≥97.3% above 1000 copies/mL. Phylogenetic analysis revealed a high homology among sequences belonging to the same subject for 96.4% of patients analysed. The overall drug-resistance prevalence was 74%. Substantial levels of resistance were found also at low viremia levels for all drug classes, with high rates for NRTI and NNRTI. In particular, detection of any drug-resistance was: 50-200 copies/mL=52.8%; 201-500=70%; 501-1000=74%; 1001-10000=86.1%; 10001-100000=76.7%; >100000=63% (P<0.001). Multivariable logistic regression confirmed that the risk of having drug-resistance was associated with viremia levels at GRT (P<0.001). The distribution of drug-resistance stratified for viral load was confirmed also considering samples only from patients failing their first-line regimen, though at a lower prevalence was observed (53% vs. 74%). This prevalence was not correlated with pretherapy viremia (P=0.441). Conclusions: In patients failing cART with viremia levels 50-1000 copies/mL, HIV-1 genotyping provides reliable and reproducible results, that are informative about emerging drug-resistance also at low viremia levels. Results may be helpful for the therapy optimization in patients under virological failure, to decrease the risk of virological failures with drug-resistance accumulation.